BIOrest Ltd.

Quick facts

Phase 2 pipeline

• LABR-312
  LABR-312's mechanism of action is currently under investigation and not fully characterized.
• Liposomal Alendronate

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• BIOrest Ltd. portfolio CI brief
• BIOrest Ltd. pipeline updates RSS